{"product_id":"pcsk9-bhn20152508","title":"PCSK9","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003ePCSK9\u003c\/strong\u003e, a plasma protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003ePlasma proteins circulate in blood and interstitial fluids, performing diverse functions including lipid transport, coagulation, immune modulation, and enzyme regulation. mRNA encoding plasma proteins such as PCSK9 can be used to transiently express these targets in cell-based systems for antibody neutralisation testing, receptor interaction studies, or as reference standards in binding-affinity measurements. The mRNA format ensures the expressed protein undergoes native co-translational folding and N-linked glycosylation in the secretory pathway, which is critical for assays that depend on correct tertiary structure.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003ePCSK9 inhibitor development: PCSK9 mRNA in hepatic cell lines (e.g., HepG2) supports studies on LDL receptor regulation, proprotein convertase activity, and anti-PCSK9 antibody neutralisation efficiency.\u003c\/li\u003e\n  \u003cli\u003ePlasma protein interaction screens: mRNA expression of plasma proteins allows cell surface or secreted protein capture for proximity ligation and co-immunoprecipitation studies under near-native conditions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eTarget engagement studies — PCSK9 mRNA expression in liver-derived cell lines supports LDL-receptor interaction assays and anti-PCSK9 antibody binding characterisation.\u003c\/li\u003e\n  \u003cli\u003eNeutralisation assays — secreted plasma protein mRNA expression as reference material for antibody potency and specificity assays in therapeutic development pipelines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003ePCSK9 expression levels and secretion into conditioned medium vary with cell line (hepatocyte vs. non-hepatocyte); HepG2 cells are typically preferred for authentic PCSK9 processing and secretion.\u003c\/li\u003e\n  \u003cli\u003eConfirm proprotein convertase processing of PCSK9 by immunoblot (mature ~60 kDa band) before using secreted material in LDL-receptor binding or antibody neutralisation assays.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239634985325,"sku":"IR0063002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239643898221,"sku":"IR0063010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239643930989,"sku":"IR0063020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239643963757,"sku":"IR0063050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239643996525,"sku":"IR0063100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239644029293,"sku":"IR0063500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_6006da41-e2b0-4d0f-bf9f-482729129bba.png?v=1776677730","url":"https:\/\/www.ebiohippo.com\/products\/pcsk9-bhn20152508","provider":"BioHippo","version":"1.0","type":"link"}